
Lilly to buy Merida for up to $2.875 billion to target rogue autoantibodies
Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion to pursue therapies that selectively degrade pathogenic autoantibodies, led by the Graves’ disease candidate MER511 in Phase 1, with additional work on MER769 for allergic diseases, expanding Lilly's autoimmune-disease portfolio.








